What to Look Forward to in 2023
CNS biopharma is rapidly investing in digital technologies to revolutionize clinical identification and monitoring of complex neurological disorders, through more objective, frequent, sensitive, and less invasive measures of movement, speech, and cognition.
Returning to Boston, the 2nd Digital Biomarkers & Clinical Measures in Neurology Summit is the only industry-specific meeting dedicated to developing translatable, scalable, and successful digital technologies and measures specifically to be incorporated into neurological clinical trials.
This is your must-attend meeting tackling the development of digital measures to revolutionize clinical assessments across neurological drug development.
Join Pioneering Digital Health Leaders to Hear From:
On showcasing takeaways from utilizing wearable sensors in decentralized clinical trials to sensitively measure gait and cognitive disease metrics
To breakdown the journey to regulatory approval of novel digital measures and methods to best instill confidence in regulatory bodies
To explore the best practices to select and validate disease-specific digital measures in neurological indications with poor anchors
On outlining key design considerations in usability of wearable and non-wearable technologies to maximize patient engagement through clinical data collection
To understand methods in digital measure rationale and design to optimize incorporation of novel measures into existing clinical trial frameworks
Who Will You Meet?
The 2nd Digital Biomarkers & Clinical Measures in Neurology Summit will bridge the gap between digital health leaders looking to discover novel devices and technologies and translational scientists eager to modernize CNS clinical development industry pioneers from digital health and translational neuroscience, including digital biomarkers KOLs, data scientists and biostatisticians, clinical innovation pioneers, wearable technology leaders, and digital regulatory experts.
Don’t miss your chance to network with 100+ industry experts from the likes of Alexion, AbbVie, Genentech, and ATAI Life Sciences at the helm of this ground-breaking momentum in digital health for neurological disorders to propel the potential of digital biomarkers in CNS trials.
What Your CNS Digital Health Peers Have to Say:
“Excellent opportunity to meet, learn, and collaborate with individuals with a vested interest in digital biomarkers and clinical endpoints for Neurology trials”
Michael Ropacki, Chief Medical Officer, CNS Clinical Development, Oryzon Genomics
“I really look forward to this conference and demonstrating what structured data can provide from real world and how this can improve care and outcomes as well as research and development”
Mark Gudesblatt, Neurologist, South Shore Neurology
“The Digital Biomarkers in Neuro Summit is an excellent opportunity to meet and discuss with pioneers in the field and move our collective knowledge up the field. This is how we will most quickly translate in vitro findings into real benefit for patients, clinicians and payors”
Arvind Tewari, Vice President, Digital Strategy & Operations, ATAI Life Sciences
“This meeting offers excellent opportunities for networking with experts from industry and academia”
Gul Erdemli, Global Program Regulatory Leader, Novartis